Abstract: The goal of this review is to highlight the most effective treatment for follicular lymphoma, however discussing different approaches of treatments but mostly to emphasize the efficient one. Three electronic databases (PubMed, Embase, and the Cochrane Library) were methodically looked for research studies evaluating the treatments for follicular lymphoma, released in English from approximately date 2016. Additional sources were recognized through searches of the American Society of Clinical Oncology (ASCO) and the European Hematology Association (EHA), and the bibliographies of included trials and current reviews. WW method is generally recommended for asymptomatic low tumor problem FL patients with advanced-stage disease, given that early systemic treatment has actually not shown benefits in OS compared to WW, and the progression-free survival and time to next treatment benefits of such techniques remain arguable. First-line rituximab monotherapy has shown really high action rates of 70 - 80%, and can produce long progression-free survival. The addition of rituximab to a number of chemotherapy routines enhanced the reaction rates, in a number of randomized controlled trials, combined rituximab plus chemotherapy (R-chemotherapy) demonstrated enhancements in total action rate, reaction duration and progression-free survival for untreated advanced-stage FL patients, and has actually shown total survival) benefits in some of these trials when compared with chemotherapy alone.
Keywords: American Society of Clinical Oncology (ASCO), European Hematology Association (EHA).
Title: Proper Diagnosis and Treatment Options of Follicular Lymphoma
Author: Alghanmi Mousa Wasal, Alfifi Abdulaziz Hassan Y, Hussain Hasan Jammal, Dheifullah Mastoor AlZaidy, Mohammed Ali K Muqri, Ahmed Mayudh Almalki, Ahmed Edah Alzhrani
International Journal of Healthcare Sciences
ISSN 2348-5728 (Online)
Research Publish Journals
